首页|艾普拉唑联合凝血酶治疗胃炎合并消化性溃疡出血的疗效及安全性探讨

艾普拉唑联合凝血酶治疗胃炎合并消化性溃疡出血的疗效及安全性探讨

扫码查看
目的 探究艾普拉唑联合凝血酶治疗胃炎合并消化性溃疡出血患者的疗效及安全性。方法 50 例胃炎合并消化性溃疡出血患者,以随机数字表法分为对照组和研究组,每组 25 例。对照组患者采取凝血酶治疗,研究组患者在对照组基础上给予注射用艾普拉唑钠治疗。对比两组疗效、生活质量、炎症因子水平和不良反应发生情况。结果 研究组临床治疗总有效率为 92。00%,明显高于对照组的 68。00%(P<0。05)。治疗后,两组生理功能、心理状况、物质生活、社会关系评分均高于治疗前,且研究组生理功能评分(80。46±4。62)分、心理状况评分(82。81±3。89)分、物质生活评分(82。11±3。49)分、社会关系评分(81。63±4。85)分均高于对照组的(75。37±3。65)、(75。18±2。83)、(72。18±3。82)、(73。52±3。17)分(P<0。05)。治疗后,两组C反应蛋白、白细胞介素-6、白细胞介素-1 水平均低于治疗前,且研究组C反应蛋白(3。35±0。79)mg/L、白细胞介素-6(40。63±5。24)ng/L、白细胞介素-1(16。43±5。16)ng/L均低于对照组的(5。59±0。57)mg/L、(62。37±3。53)ng/L、(25。18±5。14)ng/L(P<0。05)。两组不良反应发生率无统计学差异(P>0。05)。结论 对胃炎合并消化性溃疡出血患者应用艾普拉唑联合凝血酶治疗,可显著提升临床效果,改善患者血清炎症因子指标和生活质量,降低不良反应发生率,安全性较高,值得在临床推广应用。
Efficacy and safety of ilaprazole combined with thrombin in the treatment of gastritis complicated with peptic ulcer bleeding
Objective To explore the efficacy and safety of ilaprazole combined with thrombin in the treatment of gastritis complicated with peptic ulcer bleeding.Methods 50 patients with gastritis complicated with peptic ulcer bleeding were divided into a control group and a study group by random number table method,with 25 cases in each group.The control group was treated with thrombin,and the study group was treated with ilaprazole sodium for injection on the basis of the control group.The efficacy,quality of life,levels of inflammatory factors and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was 92.00%,which was significantly higher than 68.00%of the control group(P<0.05).After treatment,the scores of physiological function,psychological status,material life and social relationship in both groups were higher than those before treatment;the scores of physiological function,psychological status,material life and social relationship in the study group were(80.46±4.62),(82.81±3.89),(82.11±3.49),and(81.63±4.85)points,which were higher than(75.37±3.65),(75.18±2.83),(72.18±3.82),and(73.52±3.17)points in the control group(P<0.05).After treatment,the levels of C-reactive protein,interleukin-6 and interleukin-1 in both groups were lower than those before treatment;the study group had C-reactive protein of(3.35±0.79)mg/L,interleukin-6 of(40.63±5.24)ng/L,and interleukin-1 of(16.43±5.16)ng/L,which were lower than(5.59±0.57)mg/L,(62.37±3.53)ng/L,and(25.18±5.14)ng/L in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of ilaprazole combined with thrombin for patients with gastritis complicated with peptic ulcer bleeding can significantly improve the clinical effect,improve the serum inflammatory factors and quality of life of patients,reduce the incidence of adverse reactions,and have high safety,which is worthy of clinical promotion and application.

IlaprazoleThrombinGastritisPeptic ulcer bleedingEfficacySafety

刘振婷

展开 >

065600 永清县人民医院外三科

艾普拉唑 凝血酶 胃炎 消化性溃疡出血 疗效 安全性

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(7)
  • 15